New hope for tough blood cancers: experimental drug APG-3288 enters human testing
NCT ID NCT07424833
First seen Feb 23, 2026 · Last updated May 17, 2026 · Updated 11 times
Summary
This early-stage study tests a new oral drug, APG-3288, in about 180 adults with blood cancers like leukemia or lymphoma that returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
Conditions
Explore the condition pages connected to this study.